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for GM plants with single transformation events, the con-
troversy continues. This is due to the fact that in 2016 the 
European Commission will have to review this particular 
provision in the legislation (ibid, Article 12), and because 
of questions raised by long-term feeding studies with GM 
maize.
In response to this controversy, the European Commis-
sion-funded project GRACE (GMO Risk Assessment and 
Communication of Evidence, www.grace-fp7.eu) con-
ducted four 90-day feeding trials as well as a 1-year feed-
ing trial with the GM maize MON810 and investigated the 
scientific value of animal studies for GMO risk assessment 
in comparison with alternative studies, i.e. those not being 
performed in animals.
In recent years, animal feeding trials conducted with whole 
food/feed have been a focal issue in the controversy on 
the safety assessment of genetically modified (GM) plants 
and derived food/feed. Within the scientific community 
and among stakeholders, quite different views have been 
expressed on how these studies should be conducted, ana-
lysed and interpreted, what they might add in terms of 
information relevant to safety and whether 90-day rodent 
feeding trials should be mandatory. Despite the fact that the 
Commission Implementing Regulation (EU) No. 503/2013 
(specifying the requirements for the risk assessment of 
GM food/feed) requests mandatory 90-day feeding trials 
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In a similar approach, the current European Commis-
sion-funded project G-TwYST (GM Plants Two Year Safety 
Testing, www.g-twyst.eu) aims to inform GMO risk asses-
sors (applicants, competent authorities) and policy makers 
on the possible added value of 90-day and extended animal 
feeding studies with whole food/feed. Moreover, it aims: 
(1) to clarify uncertainties raised through the outcomes and 
reports from recent (long-term) rodent feeding studies with 
the GM maize NK603; (2) to elaborate, if proven feasible, a 
scientifically sound approach for performing feeding stud-
ies with whole food/feed based on the OECD Test Guide-
lines 408 and 453 and subsequent EFSA recommenda-
tions. In order to pursue these aims, rat feeding trials with 
GM maize NK603 are being performed to test its potential 
subchronic toxicity, chronic toxicity and carcinogenicity.
In the context of the ongoing debate on GMO risk 
assessment in Europe, it is crucial to investigate: (1) criteria 
for evaluating the scientific quality of subchronic, chronic 
toxicity and carcinogenicity studies with whole food/feed 
in rats and mice; and (2) broader societal issues includ-
ing ethical aspects associated with animal feeding trials in 
GM food/feed risk assessment. The former will help risk 
assessors in evaluating this type of studies when provided 
in the course of a pre-market risk assessment and will cre-
ate a basis for further general debate. The latter will help to 
identify and better understand the specific challenges in the 
broader debate and how scientific aspects and normative 
dimensions are interrelated. Both aspects are also targeted 
by the G-TwYST project.
This letter specifically addresses the question on how 
to evaluate whole GM food/feed feeding trials. It does so 
by proposing a list of key quality criteria for the evalua-
tion of 90-day and extended feeding trials with whole food/
feed derived from GM plants. The proposed quality crite-
ria should be taken into account when evaluating a feeding 
trial in the frame of an application to regulatory bodies and 
are not intended to be applied in other cases, in which, e.g. 
a feeding trial is performed to answer a specific open ques-
tion in basic research.
In an EFSA explanatory statement, two possible risk 
assessment scenarios were described: scenario 1: relevant 
changes and/or specific hazards were identified in preced-
ing analyses, and a feeding trial was planned and performed 
to test a specific hypothesis; scenario 2: no relevant changes 
and/or specific hazards were identified in preceding evalua-
tions (i.e. no specific endpoints are targeted), and therefore, 
there is no specific hypothesis to be tested. Even though 
from a scientific point of view such scenario 2 feeding trials 
are not warranted when the GM plants show no substantial 
changes in composition and no indications of unintended 
effects, it is important to formulate quality criteria for these 
trials, as they have been made mandatory for GM food and 
feed by the Commission Implementing Regulation (EU) 
No. 503/2013. In both scenarios, the objective of a feeding 
trial is the detection of effects elicited by diets containing 
the whole GM food/feed, which could be of toxicological 
relevance. The present letter focuses on feeding trials fall-
ing under the EFSA scenario 2.
Based on the OECD Test Guidelines 408, 451, 452 
and 453, the EFSA guidance on conducting repeated-dose 
90-day oral toxicity study in rodents on whole food/feed, 
the EFSA considerations on the applicability of OECD TG 
453 to whole food/feed testing and the EFSA explanatory 
statement on the above-mentioned EFSA guidance docu-
ment, a number of issues to be considered when wanting 
to evaluate the quality of rat and mouse feeding trials per-
formed for regulatory purposes with food/feed derived 
from GM plants were identified. As a result of extensive 
discussions on the different issues, a set of nine key quality 
criteria were identified and particular issues referring to the 
individual quality criteria were put together as described 
below. It is important to note that the described set of pro-
posed key quality criteria applies to 90-day feeding trials as 
well as to long-term feeding trials such as those performed 
to test the potential chronic toxicity and/or carcinogenicity 
of whole food/feed with a duration of 12–24 months.
Proposed criteria and issues related to each 
of them
1. The design of the feeding trial is based on internation-
ally recognized test guidelines, but adapted for specific 
needs of whole food/feed studies and non-targeted test-
ing.
There are a number of internationally recognized test 
guidelines, depending on the purpose and duration of the 
feeding trial, which can be recommended as starting points 
for the evaluation of whole food/feed. These are, among 
others, the OECD Test Guidelines 408 (90-day subchronic 
toxicity study), 451 (2-year carcinogenicity study), 452 
(1-year chronic toxicity study) or 453 (combined chronic 
toxicity/carcinogenicity study), complemented by the 
EFSA guidance on conducting repeated-dose 90-day oral 
toxicity studies in rodents on whole food/feed, the EFSA 
considerations on the applicability of OECD TG 453 to 
whole food/feed testing and/or the EFSA explanatory state-
ment on the above-mentioned EFSA guidance document. 
In the OECD documents, standardized testing protocols are 
described. However, since the OECD Test Guidelines were 
intended to evaluate chemicals, adaptations of these proto-
cols are made when wanting to test whole food/feed.
The risk assessment scenarios 1 and 2 were originally 
described by EFSA for 90-day studies. In the case of scenario 
2, in which no hypothesis to be tested has been identified, the 
study design based on the relevant OECD Test Guideline 408 
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and the corresponding EFSA recommendations is followed 
and the full range of observations/parameters described in 
the above-mentioned OECD Test Guideline is recorded. In 
the case of scenario 1, a study design of the feeding trial con-
sidering appropriate endpoints on a case-by-case basis will 
be required to test a specific hypothesis. In case of planning 
an extended feeding trial to test the potential chronic toxicity 
and/or carcinogenicity of whole food/feed derived from a GM 
plant, the protocols described in the corresponding OECD 
Test Guidelines are adapted, e.g. as described by EFSA.
Feeding trials with GM plants for regulatory purposes 
should preferably be performed following GLP principles. 
If certain parts of the study are conducted in compliance 
with GLP and others are not, this is clearly specified in the 
study report.
2. An analysis of the plant materials and diets including, 
among others, macro- and micronutrients, biological 
and chemical contaminants as well as the identification 
and quantification of the event, is performed.
A quantitative compositional analysis of the plant mate-
rials and diets is necessary to identify factors (e.g. the pres-
ence of a mycotoxin) other than the transgenic modifica-
tion that could influence the outcome of the feeding trial. 
In case that such a factor is identified, the probability that 
it could lead to unintended effects in the laboratory animals 
is considered when evaluating the outcome of the feeding 
trial. The analysis of the plant material and diets includes 
nutrients [proximates (ash, total carbohydrates, fat, pro-
tein), starch, fibres, fatty acids, amino acids, sugars, miner-
als, vitamins], and plant-specific secondary metabolites, in 
particular antinutrients (e.g. phytic acid, trypsin inhibitor, 
lectins) and toxicants as specified in the OECD Consensus 
documents for the work on the Safety of Novel Foods and 
Feeds: Plants (http://www.oecd.org/science/biotrack/con-
sensusdocumentsfortheworkonthesafetyofnovelfoodsand-
feedsplants.htm). In addition, the plant material and diets 
are tested for the presence of genetically modified organ-
isms, chemical contaminants (heavy metals, nitrosamines, 
polychlorinated dioxins, polychlorinated biphenyls, poly-
cyclic aromatic hydrocarbons, pesticides, mycotoxins) and 
the microbial contamination. Representative plant materials 
and diet samples are taken for the analyses. Based on the 
analysis of the plant material, nutritionally balanced diets 
adjusted to the dietary requirements of the rat or mouse 
strain used are formulated.
The identity of the genetic event in the plant materials 
and diets as well as the presence of other events as back-
ground contamination in the whole food/feed is docu-
mented. Moreover, depending on the availability of an 
established method, the levels of the protein encoded by the 
transgene are quantified.
3. The highest level of the plant material that can be 
incorporated in the animal diets without leading to a 
nutritional imbalance is tested.
The plant material is fed orally and ad libitum. In prin-
ciple, it is not necessary to use two dose levels in addition 
to the control (zero dose level), but in practice two dose 
levels may help in the interpretation/evaluation of results in 
order to distinguish between treatment- and non-treatment-
related effects.
EFSA suggested the following incorporation rates as 
reference values for high doses in 90-day feeding trials in 
rodents: 60 % for rice (dehulled), 50 % for maize, 30 % for 
soybean meal, 25 % for rapeseed meal and 20 % for full fat 
soybean as well as potatoes (heated, dried). In this regard, 
a preliminary “maximal inclusion rate finding study” to 
determine the maximal level of material from a specific 
plant species that could be incorporated in the animal diet 
without leading to a nutritional imbalance is conducted 
before performing a 90-day feeding trial, particularly in 
case of an incorporation rate or a plant species never having 
been tested before in a feeding trial.
When wanting to test the potential long-term effects 
(chronic toxicity and/or carcinogenicity) of whole food/
feed derived from GM plants, one has to take into account 
whether the whole food/feed incorporation rate, inde-
pendently of the event, might lead to any organ alteration 
on the long-term (i.e. within 12–24 months) due to the 
increased concentration of a normal plant constituent in 
the food/feed. In such a case, the high incorporation rate is 
reduced when compared to that used in the 90-day feeding 
trials.
4. A non-GM line with a comparable genetic background 
is used as a control.
A non-GM line with a comparable genetic background 
(i.e. near-isogenic in the case of sexually propagated crops, 
the non-GM isogenic variety in the case of vegetatively 
propagated crops) is used as a control. The control line has 
a well-established history of safe use. Moreover, the con-
trol group receives the control material at the same incor-
poration rate used for the high-dose group. If intermediate 
dose groups are included, the test material is supplemented 
with the control material in order to achieve the same total 
incorporation rate.
5. Specific aspects regarding the choice and housing of 
the laboratory animals used in the feeding trials are 
considered.
A justification for the chosen animal species (rat, mouse) 
is given. Both sexes of the chosen laboratory animals are 
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used. In the case of rats (but not in the case of mice), ani-
mals of the same sex are housed in pairs. The laboratory 
animals are housed in an animal housing facility under 
controlled conditions (e.g. room temperature: 22 ± 3 °C; 
humidity: 40–70 %; 12/12 h day and night cycle). Animals 
are acclimatized to the animal housing facility conditions 
for at least 5 days prior to the start of the study and are not 
subjected to any previous experimental procedures. Ani-
mals are uniform in age, with minimal body weight varia-
tion at the beginning of the feeding trial (i.e. ±20 % of the 
mean weight of each sex), and the age of the animals at the 
beginning of the feeding study is not greater than 9 weeks.
6. Appropriate randomization techniques are applied.
Animals are assigned to the different experimental 
groups by randomization. In this context, a randomized 
blocking, which allows to control for background varia-
tions (body weight, position of the animal in the room), is 
performed. Furthermore, where possible, the randomized 
blocking should be extended to the analysis phase (e.g. 
weighing of the animals, dissection of the animals, bio-
chemical analysis of blood and urine are to be done block 
by block). The cage is used as the experimental unit and 
considered part of the experimental design and sampling 
strategy.
7. A reliable and appropriate sample collection and pro-
cessing strategy is implemented.
Body weight and feed consumption are monitored regu-
larly. Although cage mean values are used for the statisti-
cal analysis (since the cage is the experimental unit), the 
individual animal body weight values are reported if a cage 
houses two animals.
The fasting period prior to blood sampling is the same 
for all animals. This is an important point to decrease vari-
ability in the haematology and clinical biochemical analy-
ses. Rats are fasted overnight (i.e. about 16 h), in the case 
of mice the period should only comprise 5–6 h. Blood is 
taken from the same site in all animals, and possible devia-
tions are justified. Blood is stored under appropriate condi-
tions, either without or with an anticoagulant as specified.
The clinical chemistry analyses of the blood samples 
are completed as quickly as possible, ideally within 1 day, 
to minimize potential variability between the samples. An 
analysis within 1 day might not be possible when handling 
a high number of samples, as occurs in the case of feed-
ing trials being performed according to internationally 
accepted guidelines. In such a case, the analyses are per-
formed according to a randomized sampling design (see 
criterion no. 6), where all analyses within one “sampling 
block” are done closely in time. The date of the analyses 
is recorded, and the sampling structure is considered when 
performing the statistical analyses.
Animals are necropsied in the order fixed in the rand-
omized block design of the experiment (see criterion no. 6), 
i.e. the same randomization scheme applied at the begin-
ning when assigning animals to the different experimental 
groups is applied for the gross necropsy.
8. The staff performing the feeding trial and the analy-
sis of the plant materials, diets and animal samples is 
“blind” with respect to the identity of the diets.
The advantage of a blind study is that it avoids the influ-
ence of any bias that experimenters and analysts may have 
with regard to possible outcomes. Without blinding, prior 
expectations may lead to an unconscious biasing of actions 
and observations. This is particularly relevant for those 
endpoints in which subjective elements might influence the 
observations. The blinding is applied to all staff involved, 
such as the personnel working with the animals, those that 
weigh the animals, those involved in the necropsy, and all 
analyses of material stemming from the experiments.
The dose groups are only unblinded for the histopatho-
logical evaluation of the tissues after necropsy and the 
weighing of organs. This means that in a first instance 
the tissues/organs are evaluated histopathologically in an 
unblinded manner, and in case of suspected treatment-
related findings, a blinded re-evaluation is performed.
9. Appropriate statistical methods are applied to evalu-
ate the power of the study and to analyse the obtained 
results.
A preliminary power analysis is performed to estimate 
the probability to detect effect sizes of potential relevance. 
Effect sizes of potential relevance are based on an expert 
opinion, but may also be inspired by the analysis of data-
sets from non-GM groups in previous studies with the same 
plant species and with sufficient similarity to the intended 
animal study. The power analysis requires for all parame-
ters the specification of: (a) the significance level of the test 
(this will be assumed to be 5 %, unless regulatory require-
ments justify another value); (b) the sample size (which 
will be that of the intended design); (c) the effect size (this 
will be the effect size of potential relevance); and (d) the 
variability, e.g. the standard deviation (within each dose 
group) of the measurements (this will have to be derived 
from previous data or be specified based on an expert opin-
ion). In a scenario 2, standard sample sizes (e.g. mentioned 
in OECD Test Guidelines) are used. The role of a power 
analysis is then to check the statistical power of tests for 
the different parameters to be measured. The power analy-
sis may focus on a subset of endpoints of primary interest.
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In the frame of the statistical analysis, group differences 
(effect sizes) of interest (e.g. GM group vs. control group) 
are tested for effects different from zero (difference tests). 
Finally, toxicologists assess whether the observed effects 
are relevant from a toxicological point of view by taking 
into account the complete set of measured parameters, 
whether or not the differences are significantly different.
All statistical methods are reported and comprehen-
sively described. It is important to differentiate between the 
“classical” (analysis of variance + post hoc test) and novel 
approaches (e.g. standard effect size analyses) until the risk 
assessment community has accepted the latter approaches. 
The statistical analysis plan is explicit regarding what mis-
takes/shortcomings should be avoided. Furthermore, raw 
data are made available to third parties to allow for an inde-
pendent analysis.
Concluding remarks
Taken together, nine criteria to evaluate the scientific qual-
ity of rat and mouse feeding trials with whole food/feed 
derived from genetically modified plants are proposed 
and a number of specific aspects to be taken into account 
in conjunction with these individual quality criteria are 
addressed. It is recommended that the quality assessment 
of a feeding trial in the frame of a regulatory decision pro-
cess is made on a case-by-case basis considering all rele-
vant quality criteria proposed in this letter. It is important to 
note that a feeding trial does not automatically provide use-
ful information simply because it meets the nine proposed 
criteria.
Only in case a trigger is available from the initial molec-
ular, compositional, phenotypic and/or agronomic analyses 
and therefore the rationale of the study prior to testing is 
formulated in form of hypotheses regarding specific end-
points, feeding trials with whole food/feed may provide an 
added scientific value for the risk assessment of GM crops.
It is expected that this letter will trigger a broader sci-
entific debate on the quality of rodent feeding trials with 
whole food/feed, and for this purpose, contributions are 
welcome in the Discussion Forum established by the 
scientific coordinators of the European research pro-
jects GRACE, G-TwYST and GMO90+ in Archives of 
Toxicology.
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